2021 Benchmark framework to track pharma’s progress against superbugs
07 October 2020
The rise of treatment-resistant bacterial and fungal diseases poses a direct threat both to modern medicine and our way of living. The Antimicrobial Resistance Benchmark provides the only independent measure of how pharmaceutical companies are responding. The methodology for 2021 prioritises the tracking of progress and a deeper exploration of the headwinds faced by biotechs driving novel R&D.
Drug resistance threatens all areas of healthcare, from surgery to safe childbirth. Globally, around 700,000 people die each year from antimicrobial resistance (AMR). Moreover, there are fewer experimental projects in the early-stage pipelines than in the 1990s. Plus, the impact of COVID-19 on AMR is as yet unknown, with fears that widespread use of antibiotics to prevent secondary COVID-19 infections may further drive AMR.
A core group of pharmaceutical companies is making progress against antimicrobial resistance (AMR), as reported in the 2020 Antimicrobial Resistance Benchmark. However, the 2020 report notes that change is not yet happening at the scale needed.
Read the whole article 2021 Benchmark framework to track pharma’s progress against superbugs on accesstomedicinefoundation.org.